Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language. Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.
Latest from Lisa Takagi
Multiple, wide-ranging revisions to Japan's PMD Act, including provisions on pediatric R&D, use of real-world data and cell therapies, look set to receive formal political approval within the next few months. There is also more clarity on a controversial scheme to support venture companies.
Nippon Shinyaku has revised upward its US sales forecast for DMD drug Viltepso, which has overcome multiple challenges in building its position in the US.
US private equity group to buy Japanese pharma firm in a transaction scheduled to close by September that marks owner's exit from pharma.
Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.
Oncology-focused venture eyes potential US approval for first-line use as it kicks off expanded development of light-activated therapy.